Company Filing History:
1 out of 832,891 Years Active: 2005
Title: Innovations of Eduardo A. Padlan in Antibody Technology
Introduction
Eduardo A. Padlan is a notable inventor based in Kensington, California, recognized for his contributions to the field of biotechnology, particularly in the development of modified antibodies. His innovative work focuses on creating peptides that can selectively bind to carcinoma antigens, which has significant implications for cancer diagnostics and treatment.
Latest Patents
Padlan holds a patent for "Modified antibodies with human milk fat globule specificity and uses." This patent describes an analogue peptide that includes variable regions of antibody chains, with specific amino acid substitutions that enhance binding to carcinoma antigens. The invention outlines the use of these analogue peptides in diagnostic kits for carcinomas, methods for in vivo imaging, and treatments for both primary and metastasized carcinomas. Additionally, the patent discusses the potential for these peptides to be used in ex vivo purging of neoplastic cells from biological fluids.
Career Highlights
Throughout his career, Eduardo A. Padlan has made significant strides in antibody technology. His work has led to advancements in the understanding of how modified antibodies can be utilized in medical applications, particularly in oncology. His innovative approaches have opened new avenues for research and development in cancer treatment.
Collaborations
Padlan has collaborated with esteemed colleagues such as Fernando Jose Rebelo Do Couto and Roberto L. Ceriani. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Eduardo A. Padlan's contributions to the field of biotechnology, particularly through his patented innovations in modified antibodies, demonstrate his commitment to advancing cancer diagnostics and treatment. His work continues to influence the landscape of medical research and offers hope for improved therapeutic strategies against carcinoma.